1. All Products
  2. DORA - Oral drugs
  3. AMOXICILLIN 500mg / CLAVULANIC acid 125mg, tab.
Public Pricelist

AMOXICILLIN 500mg / CLAVULANIC acid 125mg, tab.

https://medicalguidelines.msf.org/en/node/356
https://unicat.msf.org/cat/product/11853
STD DORAAMOC5T1

Valid Article

Former Code(s): -X
6.2.1 - Access group antibiotics
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.2.5 - Antituberculosis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J01CR02
Anatomical Therapeutic Chemical Classification according to WHOCC
P
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

AMOXICILLIN/CLAVULANIC acid 4:1 ratio

Therapeutic Action

Combination of two antibacterials.

The addition of clavulanic acid to amoxicillin extends its spectrum of activity to cover beta-lactamase producing Gram-positive and Gram-negative organisms, including some Gram-negative anaerobes.

Indications

Multi-drug resistant tuberculosis (MDR-TB), in combination with imipenem / cilastatin

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Amoxicillin / clavulanic acid is routinely administered prior to carbapenems, as clavulanic acid prevents the development of carbapenem resistance.

Must be given 60 min before each dose of imipenem / cilastatin.

Precautions for Use

Only formulation with a ratio 4:1 (500/125 mg) is suitable for this indication. Do not use formulations with a ratio 8:1 or 7:1.

Storage

Below 25°C ‐ Protect from sunlight ‐ Protect from humidity